FibroBiologics, Inc. Research and Development Expense
FibroBiologics, Inc. (FBLG) reported Research and Development Expense of $1.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-31
- FibroBiologics, Inc. research and development expense for the quarter ending 2026-06-30 was $1.66M, a 18.77% decline year-over-year.
- FibroBiologics, Inc. research and development expense for the quarter ending 2026-03-31 was $2.95M, a 65.90% increase year-over-year.
- FibroBiologics, Inc. research and development expense for the quarter ending 2025-12-31 was $797.00K, a 41.22% decline year-over-year.
- FibroBiologics, Inc. research and development expense for the quarter ending 2025-09-30 was $2.79M, a 129.93% increase year-over-year.
- FibroBiologics, Inc. research and development expense for fiscal 2025 was $7.41M, a 64.45% increase from fiscal 2024.
- FibroBiologics, Inc. research and development expense for fiscal 2024 was $4.50M, a 90.20% increase from fiscal 2023.
- FibroBiologics, Inc. research and development expense for fiscal 2023 was $2.37M, a 106.45% increase from fiscal 2022.
- FibroBiologics, Inc. research and development expense for fiscal 2022 was $1.15M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.66M 10-Q · filed 2026-07-31 | $4.61M 10-Q · filed 2026-07-31 | $5.41M derived: sum of 3 quarters · filed 2026-07-31 | $8.20M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $2.95M 10-Q · filed 2026-04-30 | $3.75M derived: sum of 2 quarters · filed 2026-04-30 | $6.54M derived: sum of 3 quarters · filed 2026-04-30 | $8.58M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $797.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.59M derived: sum of 2 quarters · filed 2026-02-24 | $5.63M derived: sum of 3 quarters · filed 2026-07-31 | $7.41M 10-K · filed 2026-02-24 |
| 2025-09-30 | $2.79M 10-Q · filed 2025-10-31 | $4.83M derived: sum of 2 quarters · filed 2026-07-31 | $6.61M 10-Q · filed 2025-10-31 | $7.97M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $2.04M 10-Q · filed 2026-07-31 | $3.82M 10-Q · filed 2026-07-31 | $5.18M derived: sum of 3 quarters · filed 2026-07-31 | $6.39M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $1.78M 10-Q · filed 2026-04-30 | $3.14M derived: sum of 2 quarters · filed 2026-04-30 | $4.35M derived: sum of 3 quarters · filed 2026-04-30 | $5.32M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.57M derived: sum of 2 quarters · filed 2026-02-24 | $3.54M derived: sum of 3 quarters · filed 2026-02-24 | $4.50M 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.21M 10-Q · filed 2025-10-31 | $2.19M derived: sum of 2 quarters · filed 2025-10-31 | $3.15M 10-Q · filed 2025-10-31 | $3.92M derived: sum of 4 quarters · filed 2025-10-31 |
| 2024-06-30 | $975.00K 10-Q · filed 2025-07-31 | $1.94M 10-Q · filed 2025-07-31 | $2.71M derived: sum of 3 quarters · filed 2025-07-31 | $3.28M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $960.00K 10-Q · filed 2025-05-14 | $1.73M derived: sum of 2 quarters · filed 2025-05-14 | $2.30M derived: sum of 3 quarters · filed 2025-05-14 | $2.85M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $773.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.34M derived: sum of 2 quarters · filed 2025-03-31 | $1.89M derived: sum of 3 quarters · filed 2025-03-31 | $2.37M 10-K · filed 2025-03-31 |
| 2023-09-30 | $571.00K 10-Q · filed 2024-11-12 | $1.12M derived: sum of 2 quarters · filed 2024-11-12 | $1.59M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $547.00K 10-Q · filed 2024-08-07 | $1.02M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $478.00K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $1.15M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 |